DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin

Information source: National University Hospital, Singapore
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infections Requiring Prolonged Duration (>10 Days) of Vancomycin

Intervention: continuous vancomycin infusion (Drug); intermittent vancomycin infusion (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: National University Hospital, Singapore

Overall contact:
Shire Yang Tan, Phone: 97989001, Email: shire_yang_tan@nuhs.edu.sg

Summary

This study is being carried out to find out whether there is reduction in vancomycin-induced kidney injury (nephrotoxicity) when vancomycin is given as intermittent versus continuous infusion. This study will recruit 220 subjects from 2 hospitals over a period of 3 years. Participants are invited if they have an infection that requires prolonged vancomycin therapy (> more than 10 days).

Clinical Details

Official title: Reducing Nephrotoxicity of Vancomycin: A Prospective, Randomized Study of Continuous Versus Intermittent Infusion of Vancomycin

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: nephrotoxicity

Secondary outcome: biomarkers for detection of early nephrotoxicity

Eligibility

Minimum age: 21 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adults aged 21-80 years

- Documented infection requiring prolonged (> 10 days) of vancomycin therapy

- Creatinine clearance > 50 ml/min (using Cockroft-Gault equation)

Exclusion Criteria:

- Patient already received 7 days or more of vancomycin therapy

- Pregnancy

- Severe burns > 40% body surface area

- Spinal cord injuries

- Participation in another interventional trial in previous 30 days

- Inability to obtain informed consent

Locations and Contacts

Shire Yang Tan, Phone: 97989001, Email: shire_yang_tan@nuhs.edu.sg

National University Hospital, Singapore, Singapore; Recruiting
Shire Yang Tan, Phone: 97989001, Email: shire_yang_tan@nuhs.edu.sg
Dale Fisher, Principal Investigator
Additional Information

Starting date: October 2012
Last updated: November 1, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017